Skip to content Skip to footer
Subscribe Now
Viewpoint_Dr. David_Spetzler_2020
VIEWPOINTS
PharmaShots Interview: Caris Life Sciences’ Dr. Spetzler Shares Insight on AI-Powered Clinico-Genomic Data Platform
In a recent interview with PharmaShots, Dr. Spetzler, President and Chief Scientific Officer of Caris Life Sciences shared his insights and highlights on the launch of CODEai. Shots: CODEai is a real-world clinico-genomic data platform that integrates Caris Life Sciences extensive catalog of molecular data with cancer treatment information and clinical outcomes data for ~215,000…
December 1, 20200Comments
Viewpoint_Aidan_Foley_2020
VIEWPOINTS
PharmaShots Interview: True Digital Surgery’s Aidan Foley Shares Insight on the Aesculap Aeos Robotic Digital Microscope
In a recent interview with PharmaShots, Aidan Foley, Chairman and Chief Executive Officer of True Digital Surgery shared his insights and highlights on data of the Aesculap Aeos Robotic Digital Microscope. Shots: The robotic digital microscope enables surgeons to execute precision movements in neurosurgery, spine, and ear, nose, and throat operations, through a multi-axis robotic arm. The platform utilizes…
November 26, 20200Comments
Viewpoint_Dr. Eiry_Roberts_2020
VIEWPOINTS
PharmaShots Interview: Neurocrine’s Dr. Eiry Roberts Shares Insight on Ongentys (opicapone)
In a recent interview with PharmaShots, Dr. Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences shares her insights and highlights on data of Ongentys. Shots: In a post-hoc, sub-group analysis of the P-III BIPARK-1 study demonstrated greater reductions in overnight "off" time and time to morning "on" time compared to entacapone in patients with PD…
November 16, 20200Comments
Viewpoint_Douglas_Fambrough_2020
VIEWPOINTS
PharmaShots Interview: Dicerna’s Doug Fambrough Shares Insight on Nedosiran Data Presented at ASN Week 2020
In a recent interview with PharmaShots, Doug Fambrough, Ph.D., President and CEO of Dicerna shares his insights and highlights on data of Nedosiran presented at ASN Week 2020. Shots: All participants regardless of PH subtype, achieved normal or near-normal Uox excretion @day180, 92% participants (100% & 67% with PH1 & PH2) achieved normal Uox excretion…
November 9, 20200Comments
Insight+_Senior Editor
INSIGHTS+
Insights+ Key Biosimilars Events of October 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency During the month of October, Henlius signed two agreements for its biosimilar products and presented results of HLX03 (biosimilar, adalimumab) whereas Samsung Bioepis and Biogen announced EMA filing acceptance of SB11 (biosimilar, ranibizumab) Our team at PharmaShots…
November 5, 20200Comments

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]